The latest paediatric tumours news from reliable sources can be found on the MediPaper website. Get an instant update with the latest developments in paediatric tumours.

Larotrectinib Exceeds 90% Response Rate in TRK+ Pediatric Cancers

/1 Comment/in , /by

Larotrectinib induced an “unprecedented” objective response rate of 93% in patients with TRK fusion–positive solid tumors.

Read full article (External website)

Nilotinib Granted FDA Approval for Pediatric CML

/0 Comments/in , , , /by

Based on data from 2 clinical trials, nilotinib (Tasigna) has been approved by the FDA for the first- and 2nd-line treatment of pediatric patients aged 1 year and older with Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase.

Read full article (External website)

EMA Recommends Extension of Therapeutic Indications for Fosaprepitant

/0 Comments/in , , /by

It is indicated for prevention of nausea and vomiting associated with highly and moderately emetogenic chemotherapy in adult and paediatric patients

Read full article (External website)

FDA Grants Accelerated Approval to Blinatumomab for the Treatment of B-cell Precursor ALL

/0 Comments/in , , , /by

It is indicated in adult and paediatric patients in first or second complete remission with minimal residual disease

Read full article (External website)

Asian AYA Cancer Care Survey

/0 Comments/in , /by

This survey is organised by the ESMO/SIOPE Cancer in Adolescent and Young Adults (AYA) Working Group following successful mapping of the European AYA cancer care landscape.

Read full article (External website)

Social Network Index Developed to Assess the Support Resources of Adolescent and Young Adult Cancer Survivors

/0 Comments/in , /by

A functional social network index was developed that is specific for adolescent and young adult survivors of cancer

Read full article (External website)

Larotrectinib FDA Submission Completed for TRK Fusion Cancer

/0 Comments/in , /by

A rolling new drug application has been completed for larotrectinib (LOXO-101) for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring an NTRK gene fusion.

Read full article (External website)

Oncology Breast CNS Chemotherapy Endocrine GI GU Geriatric Gynecologic GYN-OB Head and Neck Haematology Immunotherapy Lung Melanoma Skin NET Paediatric Pathology Sarcoma Surgery Targeted Therapy Translational

FDA Approves Nilotinib for Paediatric patients with Newly Diagnosed or Resistant/Intolerant Ph-Positive CML in Chronic Phase

/0 Comments/in , , , /by

2018-03-28 22:16:00

Approval is based on results in paediatric patients from CAMN107A2120 and CAMN107A2203 studies

Source